Two Sigma Advisers
ADAP

Two Sigma Advisers’s Adaptimmune Therapeutics ADAP Stock Holding History

Two Sigma Advisers’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,304
Closed -$3.19K – 2317
2025
Q2 		$3.19K Sell
13,304
-193,428
-94% -$51.6K ﹤0.01% 2300
2025
Q1 		$40.7K Buy
206,732
+135,997
+192% +$70.4K ﹤0.01% 2331
2024
Q4 		$38.1K Buy
70,735
+58,787
+492% +$42.8K ﹤0.01% 2302
2024
Q3 		$11.4K Sell
11,948
-21,389
-64% -$24.3K ﹤0.01% 2258
2024
Q2 		$32.5K Sell
33,337
-12,800
-28% -$14K ﹤0.01% 2381
2024
Q1 		$72.9K Sell
46,137
-13,700
-23% -$16.5K ﹤0.01% 2325
2023
Q4 		$47.5K Sell
59,837
-4,600
-7% -$2.59K ﹤0.01% 2403
2023
Q3 		$50.3K Sell
64,437
-32,500
-34% -$27.3K ﹤0.01% 2276
2023
Q2 		$89.7K Buy
96,937
+62,937
+185% +$75K ﹤0.01% 2224
2023
Q1 		$37.1K Buy
34,000
+3,700
+12% +$5.73K ﹤0.01% 2477
2022
Q4 		$44.2K Sell
30,300
-800
-3% -$1.3K ﹤0.01% 2372
2022
Q3 		$33K Sell
31,100
-4,200
-12% -$7.72K ﹤0.01% 2408
2022
Q2 		$60K Sell
35,300
-69,700
-66% -$120K ﹤0.01% 2457
2022
Q1 		$216K Buy
+105,000
New +$283K ﹤0.01% 2356

Other funds holding ADAP

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Two Sigma Advisers's ADAP Position: Q3 2025 in Review

Two Sigma Advisers sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 13,304 shares — an estimated $3.19K sold.

Two Sigma Advisers first reported a position in ADAP in Q1 2022 and held it in 14 quarters. The position peaked at $216K in Q1 2022. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

  • Two Sigma Advisers reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 13,304 Adaptimmune Therapeutics shares in Q3 2025, an estimated $3.19K.
  • Two Sigma Advisers first reported a position in Adaptimmune Therapeutics in Q1 2022 and held it in 14 quarters.
  • Two Sigma Advisers's Adaptimmune Therapeutics position peaked at $216K in Q1 2022.
  • 55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.